Bea Fertility
Bea Fertility (StepOne Fertility, Inc.) sells an FDA-cleared at-home intracervical insemination device and fertility coaching on a 3-cycle subscription ($399–$599) to individuals and couples trying to conceive, including heterosexual couples, LGBTQ+ families, single parents, and doctor-referred patients in the US and UK.
- Company typePrivate
- Founded2020
- HeadquartersLondon, United Kingdom
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What Bea Fertility does
Bea Fertility (legal entity StepOne Fertility, Inc., d/b/a Béa Fertility) is a fertility technology company that sells an at-home clinical fertility treatment package combining a proprietary FDA-cleared Class II medical device with nurse-led coaching. The core technology is the Béa Applicator — a cervical-cap intracervical insemination (ICI) device developed over four years and 1,000+ design tests that delivers 3.23x more sperm to the cervix than natural intercourse and holds semen against the cervix for up to five hours. Treatment is sold as two tiers: Essential Care at $399 for 3 cycles and Complete Care at $599 for 3 cycles, both HSA/FSA eligible, each kit containing two applicators and sample containers per cycle, and both including a dedicated fertility coach plus access to the Béa Treatment Hub patient portal. The company also operates a B2B2C OB/GYN referral channel with QR-code handoff and a UK NHS pilot program following its 2023 seed raise.
The company is headquartered in London with a US subsidiary in New York (Delaware-incorporated StepOne Fertility, Inc.) and serves customers in all 50 US states plus the UK. GTM is hybrid: direct-to-consumer e-commerce on beafertility.com as the primary channel, a provider-referral network with monthly encrypted progress reports to referring OB/GYNs as the secondary channel, and content marketing across blog, Instagram, Facebook, TikTok, and earned PR as the top-of-funnel motion. Pricing is package-based ($399–$599 for 3-cycle bundles) with Shop Pay Installments and HSA/FSA support. As of 2024 the company had served 1,250+ patients and shipped 3,500+ cycles, with an internal observational 39.28% pregnancy rate over three cycles (versus an often-cited 31% IUI benchmark). Investors include Octopus Ventures (seed lead), Calm/Storm VC, Forward Partners, JamJar Investments, QVentures, 7percent Ventures, and Springboard Enterprises; total disclosed equity funding is ~£2.5M (~$3.7M) in the 2023 seed plus undisclosed extension rounds.
The competitive positioning sits between natural conception (DIY insemination kits like Mosie/PherDal/Frida at ~$135/cycle and a modeled ~17.7% pregnancy rate) and clinic-based IUI (~$1,400/cycle, ~31% over three cycles), with at-home delivery, no medications, and dedicated coaching as differentiators. The product is positioned as hormone-free, OB/GYN-recommended, and supported by clinical-grade materials, with the FDA 510(k) clearance serving as the core regulatory moat. Leadership is co-founder-led (Tess Cosad, CEO; David O'Rourke, CSO/CIO) with a small executive team including a CMO and CMO medical.
Bea Fertility firmographics
Firmographics- Name
- Bea Fertility
- Legal name
- StepOne Fertility, Inc.
- Website
- https://beafertility.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Bea Fertility (StepOne Fertility, Inc.) sells an FDA-cleared at-home intracervical insemination device and fertility coaching on a 3-cycle subscription ($399–$599) to individuals and couples trying to conceive, including heterosexual couples, LGBTQ+ families, single parents, and doctor-referred patients in the US and UK.
- Ownership category
- akta.pro rank
Bea Fertility industry classification
Industry- Product category
- At-Home Fertility Treatment
- NAICS
- Family Planning Centers (621410), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation) (HLALAHAA)
- akta.pro secondary industries
- Fertility, Reproductive Endocrinology & IVF Centers (HLAFAJAD), Fertility & Ovulation Products (OTC) (CRABAIAK)
Keywords
Where Bea Fertility is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
Bea Fertility business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Fertility Treatment Kit Sales: Direct sales of at-home fertility treatment kits to consumers. Two tiers offered: Essential Care ($399 for 3 cycles) and Complete Care ($599 for 3 cycles). Each kit includes applicators, sample collection containers, and access to the Béa Treatment Hub. HSA/FSA eligible.
- Fertility Coaching Services: Included as part of treatment packages. Essential Care includes one 15-minute setup consultation with fertility coach. Complete Care includes three 30-minute video consultations (one per cycle) plus ongoing coach access via SMS/email Monday-Friday. Coaching provided by registered nurses and fertility specialists.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Essential Care - $399 for 3-cycles (~$133/cycle) |
| Subscription | Multi-year contract | Complete Care - $599 for 3-cycles (~$199.66/cycle) |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Bea Fertility product offering
Product offeringCore offering
Bea Fertility sells at-home fertility treatment kits that include an FDA-cleared Class II intracervical insemination applicator with cervical cap technology, bundled with a digital Treatment Hub and one-on-one fertility coaching delivered by trained clinicians. The kits are marketed to individuals and couples (heterosexual, LGBTQ+, and single parents by choice) seeking an at-home alternative between timed intercourse and clinical IUI.
Product overview
Béa Fertility offers an at-home clinical fertility treatment platform combining its proprietary FDA-cleared Béa Applicator (an intracervical insemination device) with fertility coaching services. The core product portfolio includes two treatment tiers: Essential Care ($399/3-cycles) with light-touch support, and Complete Care ($599/3-cycles) with comprehensive coaching. The centerpiece is the Béa Applicator, a cervical-cap device that delivers 3.23x more sperm to the cervix than natural intercourse. Treatment is supported through the Béa Treatment Hub patient portal and dedicated Fertility Coach services. All products are HSA/FSA eligible.
Differentiator
Problem solved
Functional benefit
Products and services
- Béa Treatment - Essential Care Three-cycle at-home fertility treatment kit sold for $399, including Béa Applicators, consumable Insemination Kits, Pregnancy Tests, access to the Béa Treatment Hub digital portal, and entry into the Béa fertility coaching community. Designed for individuals and couples seeking a clinician-supported at-home intracervical insemination option before escalating to clinical IUI.
- Béa Treatment - Complete Care Six-cycle at-home fertility treatment kit sold for $599, including Béa Applicators, consumable Insemination Kits, Pregnancy Tests, full Treatment Hub access, and 1:1 video fertility coaching sessions with a trained fertility clinician. Designed for higher-commitment buyers who want longer protocols and dedicated 1:1 clinician coaching.
Quantifiable outcome
- 39.28% pregnancy rate over 3 cycles (vs. 31% for IUI over 3 cycles)
- +5 more outcomes
Companies that use Bea Fertility
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles5 records
Bea Fertility technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Bea Fertility partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- NHS (UK National Health Service)coreBéa Fertility launched a pilot program with the NHS following their £2.5 million funding round. The NHS pilot enables NHS patients to access Béa's at-home fertility treatment kits, expanding access to fertility care through the public healthcare system. This represents a significant validation of the technology and a strategic channel for UK market penetration.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Bea Fertility competitors and assessment
Company assessmentEmerging players
- Natalist: Natalist sells DTC fertility and conception products (tests, supplements, lubricants). It overlaps with Béa on the TTC consumer journey but does not offer a medical insemination device.
- Modern Fertility: Modern Fertility (acquired by Ro) sells at-home hormone testing and fertility insights. It targets the same pre-clinical fertility consumer but is positioned upstream of treatment, whereas Béa is a treatment itself.
- OvuSense: OvuSense offers fertility tracking sensors and apps for ovulation prediction. It overlaps with Béa on cycle timing and TTC consumer engagement but does not deliver an insemination treatment.
Direct peers
- Mosie Baby: Mosie Baby sells the most well-known DTC at-home intracervical insemination syringe kit in the US. Béa is positioned as a more clinically-supported, FDA-cleared alternative to Mosie's syringe-based approach at a comparable per-cycle price.
- PherDal: PherDal sells a sterile, FDA-registered at-home insemination kit targeting TTC couples and LGBTQ+ families. Béa competes on a similar use case but with FDA Class II clearance and bundled coaching.
- Frida (Frida Fertility): Frida has expanded from baby care into fertility, including an at-home insemination syringe kit. Same consumer segment as Béa but without FDA-cleared device status or integrated coaching.
Broad incumbents
- Maven Clinic: Maven is a leading women's and family health virtual care platform serving employers and payers. It overlaps with Béa in fertility coaching and virtual care but does not ship a hardware insemination device.
- Carrot Fertility: Carrot is a global fertility benefits platform for employers. It is a potential channel partner and adjacent competitor for Béa's fertility services, particularly for employer-sponsored adoption.
- Kindbody: Kindbody operates fertility clinics and employer-benefit programs across the US. As a clinic-based provider, it competes with Béa on the 'where to get treated' decision rather than on at-home ICI.
- Progyny: Progyny provides employer-sponsored fertility benefits covering IUI/IVF at partner clinics. Béa could be positioned as a lower-cost pre-IUI step within a Progyny-style benefit design.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Bea Fertility social profiles
Digital presenceBea Fertility compliance and trust
Trust signalCompliance2 records
Bea Fertility financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bea Fertility leadership team
Management profileNumber of profiles
Profiles4 records
Bea Fertility funding detail
Funding detailFunding overview
Funding rounds6 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bea Fertility M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bea Fertility
What does Bea Fertility do?
Bea Fertility sells at-home fertility treatment kits that include an FDA-cleared Class II intracervical insemination applicator with cervical cap technology, bundled with a digital Treatment Hub and one-on-one fertility coaching delivered by trained clinicians. The kits are marketed to individuals and couples (heterosexual, LGBTQ+, and single parents by choice) seeking an at-home alternative between timed intercourse and clinical IUI.
Is Bea Fertility a public or private company?
Bea Fertility is a private company. It is classified as venture growth investor backed and is currently operating.
When was Bea Fertility founded?
Bea Fertility was founded in 2020. It employs 1 to 10 people.
Where is Bea Fertility based?
Bea Fertility is headquartered in London, United Kingdom, in the Europe region.
How does Bea Fertility make money?
Two revenue lines are on record. Fertility Treatment Kit Sales are the primary driver. The others are fertility Coaching Services.
Who are Bea Fertility's main competitors?
Emerging players on record are Natalist, Modern Fertility and OvuSense. Direct peers are Mosie Baby, PherDal and Frida (Frida Fertility). Broad incumbents are Maven Clinic, Carrot Fertility, Kindbody and Progyny.
Does Bea Fertility have an API?
No public API is recorded for Bea Fertility.
What industry is Bea Fertility in?
Bea Fertility's product category is At-Home Fertility Treatment. Its primary akta.pro industry code is HLALAHAA, Fertility & Reproductive Endocrinology Telehealth (IVF/IUI, infertility evaluation), with a secondary code of HLAFAJAD, Fertility, Reproductive Endocrinology & IVF Centers. Its NAICS code is 621410 and its SIC code is 3845.